SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
HuMAB companies
An SI Board Since May 2000
Posts SubjectMarks Bans
1022 55 0
Emcee:  nigel bates Type:  Unmoderated
Introduction Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
922MorphoSys Achieves Clinical Milestone and Payment in Antibody Alliance 05/05/20Germanecki-5/5/2009
921MorphoSys AG Reports Strong Results for First Quarter 2009 04/28/2009 at 07:00 Germanecki-4/30/2009
920MorphoSys Strengthens Patent Position on its Core HuCAL Technology in Europe MoGermanecki-3/13/2009
919Human Genome Sciences Begins Delivery of First-in-Class Anthrax Treatment to U.SA.J. Mullen-2/2/2009
918MorphoSys to Accelerate the Expansion and Advancement of its Proprietary PipelinGermanecki-1/20/2009
917MorphoSys Announces Second Clinical Milestone in Therapeutic Antibody Program 1Germanecki-12/11/2008
916MorphoSys Unveils New Antibody Library, HuCAL PLATINUM® 12/09/2008 at 07:3Germanecki-12/9/2008
915Centocor has started a P2 with a Morphosys-mAB! <b>A Study to Evaluate thGermanecki-11/25/2008
914Antibody Shows Ability to Inhibit Disease in an Established RA Model MorphoSys Germanecki-11/13/2008
913Full Year Profit Guidance Increased - MorphoSys AG Reports Strong Results for thGermanecki-10/30/2008
912MorphoSys Nominates First Pre-Development Program in Antibody Collaboration 09/2Germanecki-9/25/2008
911e2v to Establish Next Generation Biosensor System Using AbD Serotec-generated HuGermanecki-9/25/2008
910Mini antibodies: biotech's next big thing? By Ben Hirschler, European Pharmanigel bates-9/12/2008
909Ablynx and Merck Serono to equally contribute to discover and develop Nanobodiesnigel bates-9/4/2008
908Revenues up 16 %, Operating Profit More Than Doubled <b>MorphoSys AG RepoGermanecki-7/29/2008
907First AbD Serotec generated HuCAL Antibodies Distributed as Part of Clinical DiaGermanecki-7/17/2008
906MorphoSys and Integrated BioTherapeutics Provide Update Regarding USAMRIID BiodeGermanecki-7/17/2008
905Boehringer Ingelheim Gains Access to Additional MorphoSys Technology MARTINSRIEGermanecki-7/10/2008
904OncoMed Pharmaceuticals Extends License Agreement for Use of MorphoSys's CorGermanecki-6/18/2008
903Schering-Plough Extends Antibody Alliance with MorphoSys 19 May 2008 ThiGermanecki-5/20/2008
902Revenues up 16 %, Operating Profit Tripled MorphoSys AG Reports First Quarter 2Germanecki-4/29/2008
901DAIICHI SANKYO Extends Alliance with MorphoSys for Use of HuCAL GOLD to Develop Germanecki-3/27/2008
900And here is slightly older news on a competing program for the same (interleukinPseudo Biologist-3/17/2008
899What’s with the brand name <i>Bosatria</i>? It sounds like a small cDewDiligence_on_SI-3/17/2008
898GlaxoSmithKline says Bosatria phase III study results 'significant' LONDnigel bates-3/17/2008
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News